AbbVie, Taro settle over rosacea drug patents

Ab bVie and its exclusive licensee have settled a patent lawsuit against Taro Pharmaceutical over a generic rosacea drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

AbbVie settles longstanding trade secret dispute with Evolus

23 February 2021 AbbVie and its Korean partner Medytox have settled a trade secret dispute with competitor Evolus over the sale of a rival botox competitor drug Jeuveau.

Americas

Health campaigners call for greater checks on AbbVie/Allergan merger

20 February 2020 Trade unions and consumer groups have urged the Federal Trade Commission to intervene in the planned $63 billion merger of drugmakers AbbVie and Allergan, arguing it would “substantially harm competition”.

More on this story

Big Pharma

AbbVie settles longstanding trade secret dispute with Evolus

23 February 2021 AbbVie and its Korean partner Medytox have settled a trade secret dispute with competitor Evolus over the sale of a rival botox competitor drug Jeuveau.

Americas

Health campaigners call for greater checks on AbbVie/Allergan merger

More on this story

Big Pharma

AbbVie settles longstanding trade secret dispute with Evolus

23 February 2021 AbbVie and its Korean partner Medytox have settled a trade secret dispute with competitor Evolus over the sale of a rival botox competitor drug Jeuveau.

Americas

Health campaigners call for greater checks on AbbVie/Allergan merger